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Background
The aim of this non-interventional study was to document
the impact of a sublingual allergen immunotherapy (AIT)
with Oralair 5-grass pollen tablets (Stallergenes, France)
on symptom severity, use of symptomatic medication and
tolerability in patients with grass pollen-induced allergic
rhinoconjunctivitis (RC) over 2 years of routine medical
practice treatment. This poster focuses on the subgroups
of children (4-11 yrs) and adolescents (12-17 yrs).
Methods
This prospective, open, non-controlled, non-interven-
tional, multicenter study was conducted from September
2010 to October 2012 in Germany. Overall 1.482
patients (248 children (16.9%), 201 adolescents (13.7%))
participated in the study.
The patients rated their symptoms as a combined score
of severity (scale: 0 [none] – 3 [severe]) and frequency
(scale: 0 [none] – 4 [very often]). In the combined RC
score, the severity of rhinitis and conjunctivitis were
pooled (scale: 0 [none] – 6 [severe]).
Results
During the season preceding AIT treatment 88/ 85% of
children/ adolescents had used symptomatic medication.
This rate dropped to 57/ 56% (1st season) and to 48/ 40%
(2nd season). Likewise the RC score decreased from 4.10/
4.05 to 1.93/ 1.97 (1st year) and to 1.39/ 1.39 (2nd year).
An improvement in health status after two years of
treatment was documented by 96/ 97%.
Adverse events occurred in 17.7/ 20.2% over two years
of treatment. The incidence of non-fatal serious adverse
events was 1.2/ 0.0%.
At the end of the 2nd season, 96/ 97% evaluated the tol-
erability of the 5-grass pollen tablets as very good or good.
For the group of monoallergic children/ adolescents,
the RC score was reduced from 4.05/ 3.63 to 1.95/ 1.85
(1st year) to 1.29/ 1.10 (2nd year). The RC score in poly-
allergic children/ adolescents decreased from 4.09/ 4.17
to 1.94/ 2.03 (1st year) to 1.46/ 1.50 (2nd year).
Conclusion
Based on the study results, AIT with Oralair 5-grass
pollen tablets was well tolerated by children and adoles-
cents in routine medical practice. All symptom scores
and the symptomatic medication use were reduced sig-
nificantly after one and two years under treatment with
Oralair 5-grass pollen tablets compared to the season
preceding AIT. Polyallergic children and adolescents
benefited as much from AIT as the monoallergic ones.
Authors’ details
1Stallergenes GmbH, Kamp-Lintfort, Germany. 2Institute of Medical Statistics,
Informatics and Epidemiology (IMSIE), University Hospital Cologne, Cologne,
Germany.
Published: 28 February 2014
doi:10.1186/2045-7022-4-S1-P14
Cite this article as: Karagiannis et al.: PD14 - Non-interventional 2-year
study of sublingual immunotherapy in children and adolescents with
allergic rhinoconjunctivitis caused by grass pollen. Clinical and
Translational Allergy 2014 4(Suppl 1):P14.1Stallergenes GmbH, Kamp-Lintfort, Germany
Full list of author information is available at the end of the article
Karagiannis et al. Clinical and Translational Allergy 2014, 4(Suppl 1):P14
http://www.ctajournal.com/content/4/S1/P14
© 2014 Karagiannis et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
